Key Metrics of Exelixis
Revenue$1.8B▲ 13.6% YoYFY 2023
Operating income$171M▼ 15.2% YoY
Net profit$208M▲ 14.0% YoY
Shareholders' equity$2.3B
Market cap$16.4BEXEL · $66.20
Competitors10identified
About Exelixis
Sectors
Company details
- Website
- exelixis.com
- Founded
- 2000
- Listed
- Nasdaq: EXEL (since 2000)
Operational Areas of Exelixis
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameExelixis Inc.
TickerEXEL
ExchangeNasdaq
CountryUnited States
SEC CIK0000939767
Listed since2000
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttp://www.exelixis.com
US market & SEC filings
EXEL · Nasdaq · SEC CIK 0000939767
Last price · 30 Oct 2026
$66.20
−0.12%
Market cap$16.4B
P/E101.8On FY 2023 diluted EPS
Volume2,839,553
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited StatesListed 2000
EXEL share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeSouth San Francisco
GSTIN—
Email—
Websitehttp://www.exelixis.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Exelixis
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | 10xgenomics.com | 2019 | United States |
Similar companies
A
Adaptive BiotechnologiesPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
F
Fulgent GeneticsPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
G
Gufic Biosciences LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
R
Rossari Biotech LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
K
Kbk Biotech Private LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
Concord Biotech LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
N
Nuvation Bio Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
S
Septerna Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
biotechnology
Filings
No filings on record yet.